Effects of single-dose atorvastatin on interleukin-6, interferon gamma, and myocardial no-reflow in a rabbit model of acute myocardial infarction and reperfusion

Brazilian Journal of Medical and Biological Research

Volumn 47, Issue 3, 2014, Pages 245-251

  Zhao, X J ^a   Liu, X L ^b   He, G X ^c   Xu, H P ^a  

^a Affiliated Hospital of Binzhou Medical University   (China)

^b SHANDONG UNIVERSITY   (China)

^c THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Atorvastatin; Inflammation; Myocardial infarction; No reflow phenomenon

Indexed keywords

ATORVASTATIN; GAMMA INTERFERON; INTERLEUKIN 6; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; PYRROLE DERIVATIVE;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART INFARCTION SIZE; HEART MUSCLE REPERFUSION; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; NO REFLOW PHENOMENON; NONHUMAN; PROTEIN EXPRESSION; RABBIT; SINGLE DRUG DOSE; ANIMAL; CORONARY OCCLUSION; DISEASE MODEL; HEART MUSCLE; LIGATION; METABOLISM; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; NECROSIS; NO-REFLOW PHENOMENON; PATHOLOGY; PROCEDURES; RANDOMIZATION;

ANIMALS; ANTICHOLESTEREMIC AGENTS; CORONARY OCCLUSION; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEPTANOIC ACIDS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INTERFERON-GAMMA; INTERLEUKIN-6; LIGATION; MALE; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; MYOCARDIUM; NECROSIS; NO-REFLOW PHENOMENON; PYRROLES; RABBITS; RANDOM ALLOCATION;

EID: 84898918294     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/1414-431X20132999     Document Type: Article

References (34)

1. Gibson CM, Cannon CP, Murphy SA, Ryan KA, Mesley R, Marble SJ, et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 2000; 101: 125-130 doi: 10.1161/01.CIR. 101.2.125.
2. Schwartz BG, Kloner RA. Coronary no reflow. J Mol Cell Cardiol 2012; 52: 873-882 doi: 10.1016/j.yjmcc.2011.06.009.
3. Gersh BJ. Optimal management of acute myocardial infarction at the dawn of the next millennium. Am Heart J 1999; 138: S188-S202 doi: 10.1016/S0002-8703(99) 70342-X.
4. Kloner RA. No-reflow phenomenon: maintaining vascular integrity. J Cardiovasc Pharmacol Ther 2011; 16: 244-250 doi: 10.1177/1074248411405990.
5. Zhao JL, Yang YJ, Cui CJ, You SJ, Gao RL. Pretreatment with simvastatin reduces myocardial no-reflow by opening mitochondrial K(ATP) channel. Br J Pharmacol 2006; 149: 243-249 doi: 10.1038/sj.bjp.0706862.
6. Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, Sardella G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 2007; 49: 1272-1278 doi: 10.1016/j.jacc.2007.02.025.
7. Reffelmann T, Kloner RA. Microvascular reperfusion injury: rapid expansion of anatomic no reflow during reperfusion in the rabbit. Am J Physiol Heart Circ Physiol 2002; 283: H1099-H1107.
8. Wang CY, Liu PY, Liao JK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med 2008; 14: 37-44 doi: 10.1016/j.molmed.2007.11.004.
9. Nohria A, Prsic A, Liu PY, Okamoto R, Creager MA, Selwyn A, et al. Statins inhibit Rho kinase activity in patients with atherosclerosis. Atherosclerosis 2009; 205: 517-521 doi: 10.1016/j.atherosclerosis.2008.12.023.
10. Lefer DJ. Statins as potent antiinflammatory drugs. Circulation 2002; 106: 2041-2042 doi: 10.1161/01.CIR.0000033635.42612.88.
11. Meijer P, Oyen WJ, Dekker D, van den Broek PH, Wouters CW, Boerman OC, et al. Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection. Arterioscler Thromb Vasc Biol 2009; 29: 963-968 doi: 10.1161/ATVBAHA.108.179622.
12. Briguori C, Visconti G, Focaccio A, Golia B, Chieffo A, Castelli A, et al. Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Am Coll Cardiol 2009; 54: 2157-2163 doi: 10.1016/j.jacc.2009.07.005.
13. Briguori C, Colombo A, Airoldi F, Violante A, Focaccio A, Balestrieri P, et al. Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction. Eur Heart J 2004; 25: 1822-1828 doi: 10.1016/j.ehj.2004.07.017.
14. Iwakura K, Ito H, Kawano S, Okamura A, Kurotobi T, Date M, et al. Chronic pre-treatment of statins is associated with the reduction of the no-reflow phenomenon in the patients with reperfused acute myocardial infarction. Eur Heart J 2006; 27: 534-539 doi: 10.1093/eurheartj/ehi715.
15. Li XD, Yang YJ, Geng YJ, Zhao JL, Zhang HT, Cheng YT, et al. Phosphorylation of endothelial NOS contributes to simvastatin protection against myocardial no-reflow and infarction in reperfused swine hearts: partially via the PKA signaling pathway. Acta Pharmacol Sin 2012; 33: 879-887 doi: 10.1038/aps.2012.27.
16. Wolfrum S, Dendorfer A, Schutt M, Weidtmann B, Heep A, Tempel K, et al. Simvastatin acutely reduces myocardial reperfusion injury in vivo by activating the phosphatidylinositide 3-kinase/Akt pathway. J Cardiovasc Pharmacol 2004; 44: 348-355 doi: 10.1097/01.fjc.0000137162.14735.30.
17. Ferreira R. The reduction of infarct size - forty years of research. Rev Port Cardiol 2010; 29: 1037-1053.
18. Helmy SA, Wahby MA, El-Nawaway M. The effect of anaesthesia and surgery on plasma cytokine production. Anaesthesia 1999; 54: 733-738 doi: 10.1046/j.1365- 2044.1999.00947.x.
19. Shen Y, Wu H, Wang C, Shao H, Huang H, Jing H, et al. Simvastatin attenuates cardiopulmonary bypass-induced myocardial inflammatory injury in rats by activating peroxisome proliferator-activated receptor gamma. Eur J Pharmacol 2010; 649: 255-262 doi: 10.1016/j.ejphar.2010.08.058.
20. Stumpf C, Petzi S, Seybold K, Wasmeier G, Arnold M, Raaz D, et al. Atorvastatin enhances interleukin-10 levels and improves cardiac function in rats after acute myocardial infarction. Clin Sci 2009; 116: 45-52 doi: 10.1042/CS20080042.
21. Kostis JB, Turkevich D, Sharp J. Association between leukocyte count and the presence and extent of coronary atherosclerosis as determined by coronary arteriography. Am J Cardiol 1984; 53: 997-999 doi: 10.1016/0002-9149(84)90624-6.
22. Neri Serneri GG, Boddi M, Modesti PA, Coppo M, Cecioni I, Toscano T, et al. Cardiac angiotensin II participates in coronary microvessel inflammation of unstable angina and strengthens the immunomediated component. Circ Res 2004; 94: 1630-1637 doi: 10.1161/01.RES.0000130944.49657.b8.
23. Yeh ET, Anderson HV, Pasceri V, Willerson JT. C-reactive protein: linking inflammation to cardiovascular complications. Circulation 2001; 104: 974-975 doi: 10.1161/01.CIR.104.9.974.
24. Zhang A, Zhang H, Wu S. Immunomodulation by atorvastatin upregulates expression of gap junction proteins in coxsackievirus B3 (CVB3)-induced myocarditis. Inflamm Res 2010; 59: 255-262 doi: 10.1007/s00011-009-0093-8.
25. Link A, Ayadhi T, Bohm M, Nickenig G. Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome. Eur Heart J 2006; 27: 2945-2955 doi: 10.1093/eurheartj/ehl277.
26. Herrmann J. Peri-procedural myocardial injury: 2005 update. Eur Heart J 2005; 26: 2493-2519 doi: 10.1093/eurheartj/ehi455.
27. Maksimenko AV, Turashev AD. No-reflow phenomenon and endothelial glycocalyx of microcirculation. Biochem Res Int 2012; 2012: 859231 doi: 10.1155/2012/859231.
28. Malek LA, Spiewak M, Klopotowski M, Misko J, Ruzyllo W, Witkowski A. The size does not matter - the presence of microvascular obstruction but not its extent corresponds to larger infarct size in reperfused STEMI. Eur J Radiol 2012; 81: 2839-2843 doi: 10.1016/j.ejrad.2011.11.053.
29. Gurgun C, Ildizli M, Yavuzgil O, Sin A, Apaydin A, Cinar C, et al. The effects of short term statin treatment on left ventricular function and inflammatory markers in patients with chronic heart failure. Int J Cardiol 2008; 123: 102-107 doi: 10.1016/j.ijcard.2006.11.152.
30. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Leslie SJ, Sasiela WJ, et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 2003; 108: 1560-1566 doi: 10.1161/01.CIR.0000091404.09558.AF.
31. Sakabe K, Fukuda N, Wakayama K, Nada T, Shinohara H, Tamura Y. Lipid-altering changes and pleiotropic effects of atorvastatin in patients with hypercholesterolemia. Am J Cardiol 2004; 94: 497-500 doi: 10.1016/j.amjcard.2004.04.067.
32. Feron O, Dessy C, Desager JP, Balligand JL. Hydroxymethylglutaryl- coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 2001; 103: 113-118 doi: 10.1161/01.CIR.103.1.113.
33. Lardizabal JA, Deedwania PC. The anti-ischemic and antianginal properties of statins. Curr Atheroscler Rep 2011; 13: 43-50 doi: 10.1007/s11883-010-0147-y.
34. Gaddam V, Li DY, Mehta JL. Anti-thrombotic effects of atorvastatin - an effect unrelated to lipid lowering. J Cardiovasc Pharmacol Ther 2002; 7: 247-253 doi: 10.1177/107424840200700408.